NeuroSense Therapeutics Ltd.

General ticker "NRSN" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $29.5M (TTM average)

NeuroSense Therapeutics Ltd. does not follow the US Stock Market performance with the rate: -30.4%.

Estimated limits based on current volatility of 6.0%: low 0.41$, high 0.46$

Factors to consider:

  • Total employees count: 11 as of 2021
  • Current price 20.9% below estimated low

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2025-12-31 to 2027-12-31

  • 2025-12-31 to 2026-12-31 estimated range: [0.52$, 1.46$]
  • 2026-12-31 to 2027-12-31 estimated range: [0.47$, 1.32$]

Financial Metrics affecting the NRSN estimates:

  • Positive: with PPE of -1.4 at the end of fiscal year the price was neutral
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -38.06 <= 0.28
  • Positive: Investing cash flow per share per price, % of -0.04 > -0.64
  • Positive: Interest expense per share per price, % of 0 <= 0.01
  • Positive: Inventory ratio change, % of 0 <= 0
  • Negative: negative Net income

Similar symbols

Short-term NRSN quotes

Long-term NRSN plot with estimates

Financial data

YTD 2024-12-31 2025-12-31
Operating Revenue $0.00MM $0.00MM
Operating Expenses $9.90MM $11.09MM
Operating Income $-9.90MM $-11.09MM
Non-Operating Income $-0.31MM $-0.04MM
Interest Expense $0.31MM $0.00MM
R&D Expense $5.70MM $6.23MM
Income(Loss) $-10.21MM $-11.12MM
Net Income(Loss)* $-10.21MM $-11.12MM
Stockholders Equity $2.58MM $-1.56MM
Assets $4.58MM $1.03MM
Operating Cash Flow $-10.13MM $-7.67MM
Capital expenditure $0.00MM $0.01MM
Investing Cash Flow $0.00MM $-0.01MM
Financing Cash Flow $10.91MM $4.43MM
Earnings Per Share** $-0.55 $-0.44

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.